Last Updated: May 1, 2026

CLINICAL TRIALS PROFILE FOR THIOPENTAL SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Thiopental Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00142493 ↗ Effect of Affective Content on Drug Induced Amnesia of Episodic Memory Completed Memorial Sloan Kettering Cancer Center Phase 1 2004-09-01 The purpose of this research is to understand how some of the drugs commonly used in anesthesia impair memory. We are particularly interested in whether the emotion associated with a memory influences how well these drugs are able to block memory. We are studying four commonly used drugs-propofol, thiopental, midazolam, and dexmedetomidine, all of which may have slightly differing effects. We will also study an inactive substance, called a placebo, that should have no effect. The results of this study will provide information that will be useful in understanding how memory works, how these drugs affect memory, and possibly why some people don't have their memory blocked as easily as others.
NCT00521612 ↗ Sevoflurane vs. Isoflurane for Low-Flow General Anaesthesia for Abdominal Surgery Completed General Hospital Dubrovnik N/A 2007-09-01 Two groups of patients are going to have abdominal surgery with low-flow general anaesthesia. Group A (sevoflurane group, experimental group) will use volatile anaesthetic sevoflurane. Group B (isoflurane group, control group) will use volatile anaesthetic isoflurane. It will be observed differences between volatile anaesthetic sevoflurane and volatile anaesthetic isoflurane for providing low-flow general anaesthesia for abdominal surgery. Duration of this randomised controled trial will be approximately 2 months. Estimated sample size will be 82 persons (41 in sevoflurane group and 41 in isoflurane group).
NCT00978757 ↗ The Effect of Ketamine on Interleukin-6 Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion Completed Hospital Italiano de Buenos Aires Phase 4 2001-06-01 The purpose of this study is to determine whether ketamine is effective to inhibit interleukin 6 synthesis in hepatic resections requiring temporary porto-arterial occlusion.
NCT01005433 ↗ Dexmedetomidine for Cesarean Delivery Completed King Faisal University Phase 1 2009-12-01 Regional anesthesia has become the anesthetic of choice for cesarean section in most countries; however, some women still prefer general anesthesia techniques. There are many trials for the pharmacological modifications of the sympathetic response to surgery, including opioids, tenoxicam, ketorolac, lidocaine and paracetamol. However, opioid administration to the mother before delivery has adverse neonatal effects. This research is a novel trial on the use of dexmedetomidine for suppression of the hemodynamic and hormonal responses of cesarean delivery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Thiopental Sodium

Condition Name

Condition Name for Thiopental Sodium
Intervention Trials
Agitation 1
Memory Losses 1
Amnesia-Memory Loss 1
Nausea 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Thiopental Sodium
Intervention Trials
Emergence Delirium 2
Psychomotor Agitation 1
Tachycardia, Supraventricular 1
Amnesia 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Thiopental Sodium

Trials by Country

Trials by Country for Thiopental Sodium
Location Trials
Egypt 3
United States 1
Saudi Arabia 1
Korea, Republic of 1
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Thiopental Sodium
Location Trials
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Thiopental Sodium

Clinical Trial Phase

Clinical Trial Phase for Thiopental Sodium
Clinical Trial Phase Trials
Phase 4 4
Phase 1/Phase 2 1
Phase 1 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Thiopental Sodium
Clinical Trial Phase Trials
Completed 13
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Thiopental Sodium

Sponsor Name

Sponsor Name for Thiopental Sodium
Sponsor Trials
Ain Shams University 3
Menoufia University 1
Memorial Sloan Kettering Cancer Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Thiopental Sodium
Sponsor Trials
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Thiopental Sodium Market Analysis and Financial Projection

Last updated: April 29, 2026

Thiopental Sodium: Clinical Trial Status, Market Positioning, and Revenue Outlook

Thiopental sodium is a short-acting barbiturate used primarily for induction of anesthesia. The drug’s current commercial profile is shaped by mature use, entrenched generics, heavy regulatory scrutiny for controlled-substance handling, and limited scope for new “breakthrough” clinical programs. Public clinical-trial activity for thiopental sodium is sparse, with most available trial records being legacy studies or observational/usage-related work rather than new registrational Phase 3 programs.

What is the current clinical-trial footprint for thiopental sodium?

Publicly indexed clinical-trial activity for thiopental sodium is limited and does not show a clear pipeline consistent with near-term new approvals. Trial records that do exist tend to be small, heterogeneous, and centered on anesthesia practice questions (dose, induction workflow, alternative regimens) rather than development of a new thiopental sodium formulation intended for a registrational endpoint.

What this implies for development spend

  • No sustained, large Phase 2 to Phase 3 trajectory is visible in public registries for thiopental sodium that would indicate a credible near-term product expansion.
  • Most clinical information relevant to current practice is therefore derived from historical evidence and generics product labels, not from ongoing late-stage development.

Commercial interpretation

  • Investors and R&D sponsors generally do not fund registrational trials for an off-patent generic platform unless tied to a differentiated product attribute (route, formulation, packaging, supply chain reliability) or a new geographic regulatory pathway. Publicly, that pattern is not evident for thiopental sodium.

How does thiopental sodium sit in the market?

Thiopental sodium competes in a narrow segment: induction anesthesia where barbiturate use depends on local guideline acceptance, availability, and compliance burden (controlled procurement, handling, and administration constraints).

Market structure

  • Generic-driven pricing: Thiopental sodium is widely off-patent in major markets, driving price compression and tender-based purchasing rather than branded wholesale dynamics.
  • Supply dependence: The market is sensitive to manufacturing continuity, sterile manufacturing capacity, and controlled-substance logistics.
  • Substitution pressure: Clinicians can substitute other induction agents (not named here) based on availability, contraindication profiles, and institutional protocols, which constrains pricing power.

Commercial drivers

  1. Induction demand remains relatively stable because it is tied to anesthesia practice volumes, not a single disease area.
  2. Procurement is tenders-led in many hospital systems, which compresses ASP growth.
  3. Regulatory compliance costs are persistent and increase friction for entrants or intermittent supply.

Is there a credible path to near-term label expansion or differentiation?

For an off-patent drug, differentiation typically comes from:

  • reformulation (bioavailability, stability, or usability),
  • alternative presentation (concentration or packaging that reduces preparation steps),
  • route or delivery system changes.

Publicly visible late-stage registrational work for thiopental sodium is not evident at scale, which constrains near-term label expansion scenarios. In practice, companies focus on market access, supply reliability, and procurement inclusion rather than clinical reinvention.

What is the realistic revenue model for thiopental sodium?

Revenue is driven by volume through hospitals, ambulatory surgery centers, and anesthesiology stock replenishment cycles, with pricing determined by:

  • tender outcomes,
  • competitive generic supply,
  • regulatory classification and controlled-substance distribution constraints.

Key revenue mechanics

  • Unit economics are volume-first. ASP is structurally capped by generic competition.
  • Margins depend on manufacturing yield and sterile filling costs and on minimizing supply disruptions.
  • Working capital is meaningful where distribution timelines and controlled-substance paperwork slow replenishment.

What market projection can be supported for thiopental sodium?

Without identifiable ongoing registrational Phase 2-3 programs and without evidence of a new formulation entering late-stage development, the forward view is necessarily anchored in mature-generic dynamics.

Projected trajectory (base case)

  • Volume: broadly stable with modest fluctuation driven by surgical volume and hospital procurement cycles.
  • Price: flat-to-down due to continuing generic competition and tender pressure.
  • Revenue: stable to mildly declining in markets with intensifying generic competition, with occasional step-ups when supply tightness occurs.

Projection framework (directional)

  1. If supply remains continuous and procurement favors multiple-award contracts, thiopental sodium revenue tracks surgical procedure volumes with limited upside.
  2. If supply disruptions occur (manufacturing or regulatory), revenue may temporarily rise in the short term due to re-tendering at higher clearing prices, then revert as supply normalizes.
  3. If institutions substitute toward alternative induction agents, volume may drift down over multi-year horizons.

How do clinical-trial dynamics affect investment risk for thiopental sodium?

Because registrational-stage activity is limited, the primary risk is not clinical failure. It is operational and commercial:

  • controlled-substance compliance,
  • sterile manufacturing continuity,
  • tender competitiveness,
  • substitution risk from alternative induction agents.

Investment risk map

  • Regulatory/Compliance risk: steady, not binary.
  • Manufacturing risk: material for niche sterile supply chains.
  • Competition risk: persistent price pressure from generics.
  • Clinical adoption risk: gradual, driven by institutional protocol updates.

What should an investor or business buyer assume for near-term strategy?

For thiopental sodium, the rational near-term strategy is not “clinical pipeline expansion.” It is execution around market access and reliability:

  • secure broad inclusion in formularies and purchasing groups,
  • maintain manufacturing continuity and reduce stock-outs,
  • align packaging and concentration formats with procurement workflows.

Competitive landscape considerations

Public data support a generic-heavy landscape. In such conditions, the winning factors typically are:

  • lowest landed cost under tender rules,
  • consistent availability (no backorder),
  • acceptable lead times for controlled distribution,
  • label and presentation compatibility with institutional preparation protocols.

Key Takeaways

  • Thiopental sodium is a mature, off-patent induction anesthesia product with limited publicly visible registrational-grade clinical pipeline activity.
  • The market behaves like a stable, procurement-driven generics segment where revenue is volume-dependent and pricing is constrained by tender-led competition.
  • Near-term growth is more likely to come from supply inclusion and tender placement than from new clinical differentiation.
  • The main risk is operational and substitution-driven rather than clinical development failure.

FAQs

1) Does thiopental sodium have an active late-stage clinical development pipeline?

Publicly indexed activity does not show a sustained, large Phase 2/3 registrational pattern consistent with imminent new approvals.

2) What drives demand for thiopental sodium?

Anesthesia induction demand tied to surgical procedure volumes and hospital procurement cycles.

3) Why is pricing constrained?

Ongoing generic competition and tender-based purchasing structure.

4) What are the highest-impact business risks?

Controlled-substance compliance execution, sterile manufacturing continuity, and institutional substitution to alternative induction agents.

5) What is the most realistic path to commercial improvement?

Formulary and tender inclusion backed by reliable manufacturing and availability rather than new clinical label expansion.


References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Study records for thiopental sodium. (Accessed 2026-04-30).
[2] FDA. Drug databases and product labeling information for thiopental sodium-containing products. (Accessed 2026-04-30).
[3] European Medicines Agency (EMA). Public assessment and product information related to thiopental sodium. (Accessed 2026-04-30).
[4] World Health Organization (WHO). Essential medicines information and related barbiturate induction context. (Accessed 2026-04-30).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.